Tom, originally a veterinary scientist, has a strong track record in diagnostics and animal health and has long been involved in TB and Johne’s testing. He says it was PBD Biotech’s innovation that attracted him to the role.
Tom says: “I have been involved in TB and Johne’s testing for 15 years of my career. I licensed the AsureQuality skin test tuberculin in the US and was involved with the use of the gamma interferon test (Bovigam, Primagam and Cervigam) and the Johne’s ELISA test Parachek in laboratories worldwide.”
“What I found most interesting about PBD was their unique approach in the testing of MAP and M. bovis.”
“Also, the application of the test in many animal species and utilization for TB testing in humans.”
“I see enormous potential for the use of PBD’s technology and am excited to be a member of the team.”
Actiphage is also being trialled by State labs in the USA and Canada. This work is hugely beneficial in providing supporting evidence for the OIE validation and also in establishing traction in these important markets.
CEO Jane Theaker, based in the UK, says: “We are delighted that Tom has joined the team. He has a wealth of expertise in bovine TB testing and of the challenges faced by the North American markets.”
Tom is based in the Tampa, FL area and works closely together with Bob Lyons, Director of North American operations.
PBD Biotech has a Canadian headquarters in Saskatoon headed up by Luis Martin, which is validating the use of Actiphage for cattle and also other species important to the country’s economy, such as bison, elk and deer.
